Functional Assessment of Cancer Therapy - Lung (FACT-L)

Name of Questionnaire

Functional Assessment of Cancer Therapy – Lung, Version 4 (FACT-L v. 4)

Description

FACT-G (core instrument) plus a Lung Cancer Subscale. Developer suggests that the FACT-L may also be useful for patients with lung diseases other than cancer.

Developer

David Cella

Address

David Cella, Ph.D.
Research Professor
Institute for Health Services Research and Policy Studies
Northwestern University Director
Center on Outcomes, Research and Education
Evanston Northwestern Healthcare
1000 Central Street
Suite 101
Evanston, IL USA 60201
FAX: 847-570-1735

E-mail

d-cella@nwu.edu

URL

www.facit.org

Cost & availability

No charge for use of the English versions. Contact D Cella for permission.

Administration

Self

Time to complete

8 minutes

Number of items

36

Domains & categories

5

Name of categories/domains

Physical, social/family, emotional, and functional well-being; lung cancer subscale (symptoms, cognitive function, regret of smoking)

Scaling of items

Five-point scale from 0 (not at all) to 4 (very much)

Scoring

Subscale scores added to obtain total score. Alternative scoring includes the Trial Outcome Index (TOI), which is the sum of the Physical, Functional, and Lung Cancer Subscales. The TOI is reported to be an efficient and precise summary index of physical and functional outcomes.

Reliability

Validity

Factor analysis confirmed the hypothesized multidimensional structure of instrument¹. Correlated as expected with FLIC, M-CSDS social desirability measure, and Brief POMS¹

Responsiveness

Reported sensitivity to change in performance status over time¹

Minimally important difference

2 points on the Lung Cancer Subscale¹

Research use

Reported – paclitaxel in metastatic non-small cell lung cancer², paclitaxel and carboplatin in advanced non-small cell lung cancer³.

Clinical use

Not reported

Language

Chinese (Mainland), Danish, Dutch, English, Finnish, French, German, Hungarian, Italian, Norwegian, Spanish, Swedish

References

1. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy -- Lung (FACT-L) quality of life instrument. Lung Cancer 1995; 12:199-220.
2. Tester WJ, Jin PY, Reardon DH, et al. Phase II study of patients with metastatic non-small cell carcinoma of the lung treated with paclitaxel by 3-hour infusion. Cancer 1997; 79:724-9.
3. Roychowdhury DF, Desai P, Zhu Y-W. Paclitaxel (3-hour infusion) followed by carboplatin (24 hours after paclitaxel): a phase II study in advanced non-small cell lung cancer. Semin Oncol 1997; 24:S12-37-S12-40.

Date of information

May 1999